Spyre Therapeutics, Inc. (SYRE)

NASDAQ • Healthcare

$90.6

+$1.89 (+2.1%)

Market closed

Last close at September 11, 2026 at 20:00 UTC

Open$90

Day Range$87.89 - $91.41

Avg. Volume (3M)1.1M

Market Cap$7.8B

52 Week Range

$14.51$110.18

Next EarningsIn 51 daysNov 3, 2026

Metrics Over Time

Fundamentals & Financials

Revenue (TTM)

$90.4M

Net Income (TTM)

-$178.9M

EPS (TTM)

-$1.95

ROA (TTM)

-15.25%

Current Ratio

18.53

TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.

Income Statement

Balance Sheet

Financial Highlights

Dividends History

Split History

Earnings

+32.9%Q3 2025-$0.49

+80.3%Q4 2025-$0.15

-6.1%Q1 2026-$0.7

-12.1%Q2 2026-$0.74

+52.6%Q3 2026-$0.36

Nov 3

in 51 daysQ4 2026

% — EPS deviation from the forecast (beat / miss); quarters without a forecast show the reported EPS

View full earnings history

About Spyre Therapeutics, Inc.

Spyre Therapeutics, Inc. is a preclinical Biotechnology company listed on the NASDAQ Capital Market as SYRE that develops treatments for inflammatory bowel disease. The company focuses on drug candidates for people with ulcerative colitis and Crohn's disease, placing it in the biotech side of the healthcare sector.

Name

Spyre Therapeutics, Inc.

CEO

Cameron Turtle

Website

www.spyre.com

Industry

Healthcare

Year Founded

2013

Employees

125

Today's Snapshot

AI-generated

The day ended with SYRE 2.1% higher at 90.60, while its sector was flat. Spyre Therapeutics reported lower tissue inflammation in a Phase 2 ulcerative-colitis trial.

Trading Volume

Below 10d avg (1.2M)

871.3K

vs S&P 500 Today

Outperforming Market

+1.20%

Updated: September 11, 2026 at 20:15 UTC

Technical Indicators

3 Buy1 Neutral4 Sell

SYRE’s technical picture favors selling pressure in the short to medium term as momentum indicators are negative and volume lacks support. MACD and momentum readings are bearish and the RSI is below neutral, while ATR shows elevated volatility, which reinforces downside risk. The price sits below several medium-range moving averages despite being above long-term averages, indicating recent weakness within a longer-term higher base. On-balance volume is negative and the pivot is beneath the market but has not reversed the weakening momentum. Technical takeaway: Short- to medium-term indicators point to selling pressure despite longer-term averages remaining higher.

All signals